Qiagen launches 10-minute SARS-CoV-2 test

By LabPulse.com staff writers

August 26, 2020 -- Qiagen announced the U.S. launch of a new digital SARS-CoV-2 detection test that can be done on a portable device. The device provides results in about 10 minutes, according to the company.

The Access anti-SARS-CoV-2 total test detects antibodies in people exposed to the novel virus. It will be available in the U.S. in the coming weeks after it receives an emergency use authorization from the U.S. Food and Drug Administration.

The test, which was developed in partnership with the Australian digital diagnostics company Ellume, has been shown to have both sensitivity and specificity of 100%.

Qiagen appoints new supervisory board chairman
Qiagen has appointed Lawrence Rosen as the new chairman of its supervisory board, effective immediately. The news comes in the wake of the failure of...
Thermo Fisher's acquisition of Qiagen falls short
Thermo Fisher Scientific has terminated its acquisition of Qiagen after the company was unable to secure the number of shares needed to proceed with the...
Thermo Fisher increases Qiagen acquisition offer
Thermo Fisher Scientific and Qiagen have amended their acquisition agreement with an increase from the original offer price of 39 euros ($44.61 U.S.)...
Qiagen launches therascreen BRAF test
Qiagen is launching a therascreen BRAF test as a companion diagnostic to Pfizer's targeted drug Braftovi in metastatic colorectal cancer.
Qiagen gets FDA nod for syndromic SARS-CoV-2 test
Qiagen has received emergency use authorization from the U.S. Food and Drug Administration for its QIAstat-Dx diagnostic kit, a syndromic test for detecting...

Copyright © 2020 LabPulse.com

Last Updated bc 8/26/2020 1:51:51 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.